VAXNEUVANCE
Pre-filled syringe 1
registration number
56/30.1/0535
What VAXNEUVANCE is and what it is used for
VAXNEUVANCE is a vaccine indicated in infants, children and adolescents from 6 weeks through 17 years of age (prior to the 18th birthday) for active immunisation for the preventionof invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F.
VAXNEUVANCE is indicated in adults 18 years of age and older for active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F.
dosage
Infants may receive up to 3 doses of the vaccine through 6 months of age based on official recommendations. An additional dose is given to toddlers between 11 through 15 months of age. Your healthcare provider will tell you when your child should receive their next dose.
If your child did not receive all doses according to official recommendations, your healthcare provider may recommend doses to help them catch up.
Adults need one dose of the vaccine.
how to take
For intramuscular use only. Do not inject intravascularly.
The preferred site for injection is the anterolateral aspect of the thigh in infants or the deltoid muscle of the upper arm in children and adults. The vaccine should not be injected in the gluteal area or areas where there may be a major nerve trunk and/or blood vessel.
What VAXNEUVANCE contains
Each 0,5 mL dose contains 32 μg of total pneumococcal polysaccharide (2,0 μg each of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F, and 4,0 μg of polysaccharide serotype 6B) conjugated to 30 μg of CRM197 carrier protein, and 125 μg of aluminium (as aluminium phosphate adjuvant).
other ingredients
Sodium chloride (NaCl), L-histidine, polysorbate 20 and Water for injections.
Therapeutic classification
A.30.1 Biologicals – Antigens.